ard-101
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Nov 12, 2021 (NCT05121441)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06828861 | Phase 3 | Dec 20, 2024 | Aardvark Therapeutics, Inc. |
| NCT07197034 | Phase 3 | Jul 23, 2024 | Aardvark Therapeutics, Inc. |
| NCT05215847 | Phase 2 | Mar 1, 2022 | Aardvark Therapeutics, Inc., University of California, San Diego |
| NCT05153434 | Phase 2 | Dec 15, 2021 | Aardvark Therapeutics, Inc., University of Colorado |
| NCT05121441 | Phase 2 | Nov 12, 2021 | Aardvark Therapeutics, Inc., University of California, San Diego |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2021 |
| University of California, San Diego | Academic/Hospital | 2 | 0 | 1 | 2021 |
| University of Colorado | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1